- Report
- August 2026
- 30 Pages
Global
From €2500EUR$2,750USD£2,149GBP
- Report
- July 2026
- 147 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- July 2026
- 143 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- July 2026
- 224 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Clinical Trials
- May 2026
- 60 Pages
Global
From €1136EUR$1,250USD£977GBP
- Report
- November 2025
- 200 Pages
Global
From €7226EUR$7,950USD£6,213GBP
- Report
- November 2025
- 200 Pages
Global
From €7226EUR$7,950USD£6,213GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2535EUR$2,789USD£2,180GBP
- Report
- August 2026
- 115 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 180 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 185 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- April 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- April 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- February 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- May 2026
- 210 Pages
United States
From €4409EUR$4,850USD£3,790GBP
- Report
- February 2026
- 150 Pages
United States
From €4409EUR$4,850USD£3,790GBP
- Report
- November 2024
- 600 Pages
Global
From €3000EUR$3,300USD£2,579GBP
- Report
- May 2025
- 90 Pages
Global
From €5408EUR$5,950USD£4,650GBP
- Report
- July 2025
- 80 Pages
United States
From €5408EUR$5,950USD£4,650GBP
- Report
- January 2025
- 100 Pages
Global
From €5408EUR$5,950USD£4,650GBP

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated.
The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use.
Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more